IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study
Chen, Jing-Xu1; Su, Yun-Ai2; Bian, Qing-Tao1; Wei, Li-He1; Zhang, Rong-Zhen1; Liu, Yan-Hong1; Correll, Christoph3; Soares, Jair C.4; Yang, Fu-De1; Wang, Shao-Li1; Zhang, Xiang-Yang1,4
关键词Risperidone Aripiprazole Prolactin Hyperprolactinemia Intervention Placebo Controlled Trial Dose Effect
刊名PSYCHONEUROENDOCRINOLOGY
2015-08-01
DOI10.1016/j.psyneuen.2015.04.011
58页:130-140
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism ; Neurosciences ; Psychiatry
研究领域[WOS]Endocrinology & Metabolism ; Neurosciences & Neurology ; Psychiatry
关键词[WOS]ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA ; PALIPERIDONE-INDUCED HYPERPROLACTINEMIA ; DOPAMINE PARTIAL AGONIST ; SCHIZOAFFECTIVE DISORDER ; SCHIZOPHRENIA-PATIENTS ; RECEPTOR OCCUPANCY ; PROLACTIN LEVELS ; CONTROLLED TRIAL ; POLYPHARMACY ; MULTICENTER
英文摘要

Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/nnl for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5 mg/day (n = 30), 10 mg/day (n = 29), or 20 mg/day (n = 30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (>= 30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20 mg/day groups than the 5 rng/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects. (C) 2015 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000356738700013
项目编号2009D003014000001
资助机构Funding for Beijing Outstanding Talent Training Projects, China
引用统计
被引频次:19[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57833
专题北京大学精神卫生研究所
中国药物依赖性研究所
北京大学第三临床医学院_医院感染管理科
北京大学精神卫生研究所_精神科
作者单位1.Peking Univ, Beijing Hui Long Guan Hosp, Beijing 100096, Peoples R China
2.Peking Univ, Hosp 6, Inst Mental Hlth, Key Lab Mental Hlth,Minist Hlth, Beijing 100871, Peoples R China
3.Zucker Hillside Hosp, Psychiat Res North ShoreLong Isl Jewish Hlth Syst, Glen Oaks, NY USA
4.Univ Texas Hlth Sci Ctr Houston, Harris Cty Psychiat Ctr, Dept Psychiat & Behav Sci, Houston, TX 77030 USA
推荐引用方式
GB/T 7714
Chen, Jing-Xu,Su, Yun-Ai,Bian, Qing-Tao,et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study[J]. PSYCHONEUROENDOCRINOLOGY,2015,58:130-140.
APA Chen, Jing-Xu.,Su, Yun-Ai.,Bian, Qing-Tao.,Wei, Li-He.,Zhang, Rong-Zhen.,...&Zhang, Xiang-Yang.(2015).Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.PSYCHONEUROENDOCRINOLOGY,58,130-140.
MLA Chen, Jing-Xu,et al."Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study".PSYCHONEUROENDOCRINOLOGY 58(2015):130-140.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Jing-Xu]的文章
[Su, Yun-Ai]的文章
[Bian, Qing-Tao]的文章
百度学术
百度学术中相似的文章
[Chen, Jing-Xu]的文章
[Su, Yun-Ai]的文章
[Bian, Qing-Tao]的文章
必应学术
必应学术中相似的文章
[Chen, Jing-Xu]的文章
[Su, Yun-Ai]的文章
[Bian, Qing-Tao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。